Save for clinic
📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications
🎯 Clinical Bottom Line
OlympiA demonstrated that one year of adjuvant olaparib significantly reduced invasive disease recurrence or death in patients with germline BRCA1/2-mutated, HER2-negative, high-risk early breast cancer after chemotherapy. The benefit was consistent across TNBC and HR+ subsets, and across BRCA1 and BRCA2 carriers. This trial established a new standard of care for this molecularly selected population.
Key Result: 3-year IDFS — 85.9% (olaparib) vs 77.1% (placebo), HR 0.58 (99.5% CI 0.41–0.82; P<0.001)
Safety Signal: Grade ≥3 anemia in 8.7% of olaparib patients; 25.0% required dose reduction; 5.8% required blood transfusion
✅ Patient Eligibility
Must Have:
- Germline BRCA1 or BRCA2 pathogenic/likely pathogenic variant
- HER2-negative breast cancer
- Completed definitive local treatment + neoadjuvant or adjuvant chemotherapy (≥6 cycles anthracycline/taxane-based)
- TNBC adjuvant: node-positive or tumor ≥2 cm
- TNBC/HR+ neoadjuvant: residual invasive disease (no pCR)
- HR+/HER2− adjuvant: ≥4 positive lymph nodes
- HR+ neoadjuvant: no pCR with CPS+EG score ≥3
Cannot Have:
- HER2-positive disease
- pCR after neoadjuvant chemotherapy (for NACT patients)
- Prior PARP inhibitor therapy (per label)
💊 Dosing Quick Guide
Experimental Regimen
Olaparib: 300 mg orally twice daily Duration: 52 weeks (1 year)
Control Regimen
Placebo: matching tablets orally twice daily for 52 weeks
Key Dose Modifications [2]
Per FDA prescribing information — not trial protocol - First reduction: 250 mg twice daily - Second reduction: 200 mg twice daily - Hold for grade ≥3 hematologic toxicity; resume at reduced dose once resolved to ≤grade 1 - Monitor: CBC before initiation and monthly during therapy
Mechanism: Olaparib is a PARP inhibitor that blocks single-strand DNA repair, causing synthetic lethality in cells with defective homologous recombination (BRCA1/2 mutated) [2].
⚠️ Safety Snapshot
| Grade ≥3 Toxicities | Olaparib (n=911) | Placebo (n=904) |
|---|---|---|
| Anemia | 79 (8.7%) | 3 (0.3%) |
| Decreased neutrophil count | 44 (4.8%) | 7 (0.8%) |
| Decreased white-cell count | 27 (3.0%) | 3 (0.3%) |
| Fatigue | 16 (1.8%) | 4 (0.4%) |
| Nausea | 7 (0.8%) | 0 |
⚠️ Anemia: Any grade 23.5% vs 3.9%; Grade ≥3 8.7% vs 0.3%; Blood transfusion required 5.8% vs 0.9%
Key safety metrics:
- Serious AEs: 8.7% vs 8.4%
- Discontinuations due to AE: 9.9% vs 4.2%
- Dose reductions: 25.0% vs 5.2%
- AE leading to death (Grade 5): 1 (0.1%) vs 2 (0.2%)
- MDS/AML: 2 (0.2%) vs 3 (0.3%) — no excess risk at interim
📊 Key Numbers
Median follow-up: 2.5 years (IQR 1.5–3.5)
| Outcome | Olaparib | Placebo | HR (99.5% CI) | p-value |
|---|---|---|---|---|
| 3-yr IDFS (primary) | 85.9% | 77.1% | 0.58 (0.41–0.82) | P<0.001 |
| 3-yr DDFS | 87.5% | 80.4% | 0.57 (0.39–0.83) | P<0.001 |
| 3-yr OS | 92.0% | 88.3% | 0.68 (0.44–1.05)* | P=0.02** |
OS reported with 99% CI per hierarchical testing plan *Did not cross prespecified interim boundary of P<0.01
🔬 Key Comparator Context
| Trial | Regimen | Population | Primary Endpoint | Key Result | Ref |
|---|---|---|---|---|---|
| OlympiA | Olaparib 300 mg BID × 1 yr vs placebo | gBRCA+ HER2− high-risk early BC | 3-yr IDFS | HR 0.58; P<0.001 | [1] |
| CREATE-X | Capecitabine × 6–8 cycles vs control | HER2− early BC, residual disease after NACT | DFS | see [4] | [4] |
| KEYNOTE-522 | Pembro + chemo → pembro vs placebo + chemo → placebo | Early TNBC | pCR + EFS | see [5] | [5] |
Cross-trial comparisons are limited by differences in populations, designs, and endpoints.
🔍 Subgroups to Watch
Neoadjuvant chemo: HR 0.56 (95% CI 0.41–0.75) — consistent benefit Adjuvant chemo: HR 0.60 (95% CI 0.39–0.90) — consistent benefit BRCA1: HR 0.52 (95% CI 0.39–0.70) — consistent BRCA2: HR 0.52 (95% CI 0.30–0.86) — consistent Prior platinum — Yes: HR 0.77 (95% CI 0.49–1.21) — CI crosses 1.0; numerically smaller benefit Prior platinum — No: HR 0.52 (95% CI 0.39–0.69) — robust benefit HR+/HER2−: HR 0.70 (95% CI 0.38–1.27) — CI crosses 1.0; small subgroup TNBC: HR 0.56 (95% CI 0.43–0.73) — robust benefit
Subgroup analyses were not powered for formal comparisons. Results are hypothesis-generating.
📋 Regulatory Status
| Region | Status |
|---|---|
| FDA | Approved (March 2022) for adjuvant gBRCAm HER2− high-risk early BC after chemotherapy [2] |
| EMA | Approved for adjuvant gBRCAm HER2− high-risk early BC |
⚠️ Verify current regulatory status before prescribing.
NCCN: Category 1 recommendation for adjuvant olaparib × 1 year in eligible gBRCA+ HER2− early BC patients [3]
Companion diagnostic: BRACAnalysis CDx (Myriad Genetics) — FDA-approved for patient selection [2]
⚡ Grey Zones
- OS trend (HR 0.68; P=0.02) did not cross prespecified interim boundary — final OS analysis awaited
- Sequencing with capecitabine and pembrolizumab in post-NACT residual disease unclear — no direct comparative data
- Prior platinum subgroup showed attenuated benefit (HR 0.77 vs 0.52 without platinum) — hypothesis-generating
- HR+/HER2− subgroup too small for precise benefit estimation (HR 0.70; CI 0.38–1.27)
- Long-term MDS/AML risk in this younger population requires extended follow-up beyond 2.5 years
- Patients achieving pCR after neoadjuvant chemotherapy were excluded — benefit in lower-risk gBRCA+ patients unknown
📖 Full Analysis
Read the complete desktop article with full efficacy tables, safety detail, subgroup data, comparator trials, and clinical implications at kill-cancer.com
About the Author
Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.
📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum
For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.
References
- Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394-2405. doi:10.1056/NEJMoa2105215
- Olaparib (Lynparza) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2026. Accessed March 2026.
- Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147-2159.
- Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556-567.